An interventional study of LT-300 Active (PBM) and LT-300 Inactive (Sham) in Age Related Macular Degeneration, sponsored by LumiThera, Inc.. Completed at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by LumiThera, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Macular Degeneration with a site in Canada — 11 open to participants now, 16 under way, 7 of them phase 3. Macular Degeneration · Canada.
Among the 94 studies in Macular Degeneration with a site in Canada, this one is the 67th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2016, is one of 18 with no phase, and was the 53rd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →11 of the 94 studies in Macular Degeneration with a site in Canada are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 60+
AbbVie · Sites in Canada, United States, Austria and 14 more countries
Ages 50+
ONL Therapeutics · Sites in Canada, United States, Austria and 9 more countries
Ages 55+
Kriya Therapeutics, Inc. · Sites in Canada, United States, Israel and 1 more country
Ages 55–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 31 · Phase 4 11
First in 1999; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 180 across the 77 interventional studies, 169 across the 17 observational. Of the 63 that completed or were terminated, 26 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 94 have an industry lead sponsor. The 10 most frequent:
LumiThera, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
LumiThera, Inc. has 6 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Degeneration with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129239Phase 3Clinique de Retine de l'estHigh Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) | 2027-02 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT04762368University of WaterlooLearning Study: Improving Vision in Adults With Macular Degeneration | 2026-12 |
| NCT07917715Clarity Eye InstituteMacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration | 2027-08-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Macular Degeneration with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.
The LumiThera LT 300® Light Delivery System is a stationary desktop instrument used to emit energy in the visible and near infrared spectrum. The LT-300® is designed for the ophthalmologist to use in the treatment of the eye with photobiomodulation (PBM), a process by which cellular mechanisms are induced by light. PBM is being utilized in many indications, such as wound healing, soft tissue injuries, joint pain, myofascial pain, nerve injuries, muscle fatigue for temporary improvement in blood flow and reduction in inflammation. The mechanism of PBM at the cellular level has been ascribed to the activation of mitochondrial respiratory chain components resulting in stabilization of metabolic function and initiation of a signaling cascade, which promotes cellular proliferation and cytoprotection. The LT-300® will provide a preset treatment of PBM to the subject's eye and retinal tissue through the open and closed eyelid.
Approximately 30 subjects meeting the eligibility requirements of the study will be randomly assigned in a 1:1 ratio to receive standard of care treatment for Dry AMD plus PBM treatment with the LT-300 system, or standard of care treatment for Dry AMD plus Sham treatment with the LT-300 system. Subjects randomized to each group will receive two 3-week treatment sessions (9 treatments per session) and follow-up visits extending to one year. The primary objective of the study is to evaluate the safety and efficacy of PBM with respect to visual and anatomical outcomes of subjects with Dry AMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
Device: LT-300 Active (PBM)
Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
Device: LT-300 Inactive (Sham)
Visual Acuity changes from baseline to month 12.
Visual acuity will be measured using ETDRS VA letter scoring to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12
Time frame: Through study completion, an average of one year.
Contrast Sensitivity
Contrast Sensitivity will be measured using the FACT Contrast Sensitivity Chart to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12
Time frame: Through study completion, an average of one year.
Optical Coherence Tomography (OCT)
OCT will be measured using the Spectralis SD-OCT to compare changes in dry AMD pathology.
Time frame: Through study completion, an average of one year.
Plan to share: Undecided
The record gives a start of Mar 2016, a primary completion of Jul 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LumiThera, Inc.